TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02633449

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 100 minutes, two sessions per week for a total of six weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham-tDCS
Description: sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
Study: NCT00522392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Given PO
Study: NCT02109081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01485978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to ramipril
Description: Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.

Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Description: Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
Study: NCT04268134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplement
Description: 4 capsules taken by mouth each day for 24 weeks (starting at the week 12 visit).
Study: NCT05057390

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: New Human Milk Fortifier (NHMF)
Description: The case study product will be added to human milk during the hospitalization and will continue after discharge for at least 1 week (7 days), to obtain community data. NHMF prescription will be specified on an individual basis by the investigating Dietitian responsible for the infant's nutritional management. The intervention period will end when the infant does not require NHMF (according to local neonatal guidelines and/or clinical indication).~The case study product will be labelled specifically for the case study and will be available in a powder format.~Full preparation, storage and safety instructions will be given to the parent/caregiver by the investigating Dietitian before commencing the case study product to ensure its correct and safe use.
Study: NCT02064764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Front Advance™ Cardiac Cryoablation System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arctic Front Advance™ Cardiac Cryoablation System
Study: NCT02608788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acular®
Description: 5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
Study: NCT03122990

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FM-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame.
Study: NCT03211182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle modification intervention
Description: healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI\>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
Study: NCT00542191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin
Description: DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Definitive Surgery
Description: Standard of care definitive surgery as determined by medical provider

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Standard of care RADIATION THERAPY as indicated
Study: NCT02119715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF 100μg/kg
Description: Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated rhG-CSF:150 μg/kg
Description: Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF 5 μg/kg/day
Description: Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
Study: NCT01015508

Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Energy Diet (VLED)
Description: a VLED (Modifast) for 2 months in order to reduce body weight

Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Energy Diet (VLED)
Description: a VLED (Modifast) for 2 months in order to reduce body weight

Intervention type: OTHER
Group type: OTHER
Intervention: Very Low Energy Diet (VLED)
Description: a VLED (Modifast) for 2 months in order to reduce body weight

Intervention type: OTHER
Group type: OTHER
Intervention: Weight maintenance
Description: 10 months

Intervention type: OTHER
Group type: OTHER
Intervention: Weight maintenance
Description: 10 months

Intervention type: OTHER
Group type: OTHER
Intervention: Weight maintenance
Description: 10 months
Study: NCT05202457

Intervention type: PROCEDURE
Intervention: Elective surgery
Description: Patient undergoing elective or urgent surgery
Study: NCT03015103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intimate Lubrificant Gel
Description: All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
Study: NCT03071029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly PAFP rates displayed at clinics.
Description: Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
Study: NCT01900964

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE membrane
Description: The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
Study: NCT02620904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mifepristone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02738671

Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: Only a subgroup of the subjects will have the bariatric surgery.
Study: NCT03006627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative morphine
Description: Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: postoperative morphine
Description: Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
Study: NCT01582880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Used to treat donor cornea before implantation
Study: NCT04381767

Intervention type: DEVICE
Intervention: EYE-SYNC
Description: Evaluation of oculomotor performance using visual presentation and eye tracking analysis
Study: NCT03420560

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: warmer temperature
Description: Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: warmer temperature
Description: Patients before general anesthesia induction will send to warmer operation Injection pain was accessed with (Visual analogous scale)VAS.
Study: NCT00079378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00956930

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 glass microspheres
Description: Patients undergo radioembolization.
Study: NCT01615497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBT4CBT for alcohol plus TAU
Description: Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
Study: NCT00956930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg fixed dose
Study: NCT01835184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib-s-malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02812199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite Removable Sinus Stent
Description: Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Composite Removable Sinus Stent
Description: Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline-lidocaine
Description: adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenaline-lidocaine
Description: adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold saline wash
Description: nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
Study: NCT01900964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Description: A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
Study: NCT00639028

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle echography
Description: Ankle echography
Study: NCT01795612

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: physical activity
Study: NCT01615497

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based CBT with minimal clinical contact
Description: Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
Study: NCT01975857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Education
Description: This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
Study: NCT03709576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transplant
Description: Although hematopoietic stem cell transplantation (HSCT) is curative for many patients with AML, AML in relapse at the time of transplant is still a major challenge with low rates of leukemia-free survival even with an intensive myeloablative conditioning.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: To assess the toxicity and efficacy of a combination of Pevonedistat and Azacitidine as post allogeneic hematopoietic stem cell transplant maintenance therapy for non-remission AML.
Study: NCT02338908

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
Study: NCT00639028

Intervention type: OTHER
Group type: OTHER
Intervention: Ankle echography + stress radiography
Description: Ankle echography + stress radiography

Intervention type: OTHER
Group type: OTHER
Intervention: stress radiography
Description: ankle stress radiography
Study: NCT04707040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive Exercise Program
Description: Neurocognitive Exercise Program (NEP) is defined as a multimodal exercise program including different motor coordination exercises and cognitive tasks. Exercise progression is performed from easy to difficult, and consist of simple and complex tasks. Different sports equipment (such as different sizes of balls, racket, tulle, pilates ball, eye band, rope, etc.) is used in motor coordination exercises where multiple extremities can be used in NEP. These materials are used during different exercises including cross-limb movements, throwing, jumping, walking, involving different cognitive tasks. The cognitive task used and the degree of difficulty of the task are provided by different visual (colored cards, numbered cards, gestures, etc.) or auditory (keywords, ring signal, etc.) signs. For example, showing a red card might indicate throwing a ball with the left hand, while showing a blue card indicates throwing a ball with the right hand and walking forward
Study: NCT04176029

Intervention type: DEVICE
Intervention: lung ultrasound
Description: Lung ultrasound is performed using an 12-regions technique i.e. six areas on each side of the chest, two ventral, two lateral and two posterior. The lung ultrasound examination is estimated to take around 10 minutes of time.
Study: NCT02357732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Study: NCT02338908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP-DN
Description: In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
Study: NCT02009384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: administration of IV ipilimumab for up to 4 cycles
Study: NCT02530047

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MSC-INFβ
Description: MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.~Starting dose: 10\^5 MSC/kg once a week for 4 treatments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom questionnaire completed once a week for 4 weeks.
Study: NCT01402427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intraarterial administration of 10 mL saline.
Study: NCT03015480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote counseling
Description: For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a dietitian follow-up phone call around 5 and 11 months later.
Study: NCT02595645

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polypectomy and NGS
Description: NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
Study: NCT04397770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate
Description: apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Injection
Description: Temozolomide is an imidazole tetrazine derivative of the alkylating agent dacarbazine.Temozolomide is not directly active but undergoes rapid, spontaneous, non-enzymatic conversion at physiologic pH to the cytotoxic compound, monomethyl triazeno imidazole carboxamide (MTIC).
Study: NCT03838809

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surface electromyography-biofeedback
Description: Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: surface electromyography-biofeedback
Description: Two electrodes were putted on the motor point of the extensor muscle of the hand and the foot. The positive electrode was placed on the distal zone of the hand or the foot, while the negative electrode was placed on the proximal zone.
Study: NCT02225613

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spa protocol
Study: NCT03231683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model